**Trading Alerts**

**Trading Suspensions** - 603843 *ST Zhengping - 000698 Shenyang Chemical Industry - 002571 Deli Corporation

**Trading Resumptions** - 300506 *ST Mingjia

**Major Corporate Events**

**Deli Corporation**: Stock suspended due to planned change in company control Deli Corporation announced that on September 30, the company received notification from controlling shareholder and actual controller Shi Weidong regarding his planning of a change in company control. The specific transaction plan and agreement terms require further demonstration and negotiation. This matter may result in changes to the company's controlling shareholder and actual controller. The company's stock will be suspended starting from market opening on October 9 (Thursday), with an expected suspension period not exceeding 2 trading days.

**Sichuan Gold**: Successfully acquired exploration rights for Xinjiang Gaochang Kugezi-Juebei gold mine through competitive bidding Sichuan Gold announced that on August 13, the Xinjiang Uygur Autonomous Region Department of Natural Resources commissioned the Xinjiang Uygur Autonomous Region Government Service and Public Resource Trading Center to publish the "2025 Xinjiang Bole Shaerxili Hotel Geothermal Survey and 9 Other Exploration Rights Listing Announcement." On September 30, the company won the Xinjiang Gaochang Kugezi-Juebei gold mine exploration rights for 510 million yuan. The exploration area is located in China's important gold mineralization belt - the Central Tianshan metallogenic belt. The ore body is controlled by northwest-southeast trending anticlines and faults. The exploration area's gold anomaly zone extends several kilometers, consistent with the ore-controlling structure direction, featuring superior metallogenic geological conditions and significant exploration potential.

**ST Gaohong**: Received advance notice of delisting termination ST Gaohong announced that on September 30, 2025, the company received a "Delisting Termination Advance Notice" from the Shenzhen Stock Exchange. The company's stock closing prices were all below 1 yuan for twenty consecutive trading days from September 1 to September 26, 2025, triggering delisting conditions. The company has the right to apply for a hearing within five trading days of receiving the notice, or submit written statements and defenses within ten trading days. If the Shenzhen Stock Exchange ultimately decides to delist the company's stock, it will be transferred to the delisting board for quotation transfer.

**Baili Tianheng**: BL-ARC001 receives clinical trial approval for advanced solid tumor treatment Baili Tianheng announced that it recently received an official "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA). The company's independently developed innovative drug Lutetium [177Lu]-BL-ARC001 injection (abbreviated as "BL-ARC001") has been approved for clinical trials for advanced solid tumors. BL-ARC001 is the company's first Class I innovative drug in the antibody-radioisotope conjugate (ARC) field and represents a potentially first-in-class ARC drug with complete independent intellectual property rights. BL-ARC001 utilizes antibody-mediated precision targeting delivery technology and the powerful tumor-killing capability of radioisotopes. Compared to traditional radioisotope conjugate drugs, it demonstrates stronger target specificity, higher tumor accumulation, and is expected to show better resistance to drug resistance.

**Xingye Yinxi**: Stock price volatility attributed to significant market price fluctuations of main products silver and tin Xingye Yinxi announced that the company's stock closing prices showed cumulative deviation of 20.78% over three consecutive trading days (September 26, 29, and 30), meeting Shenzhen Stock Exchange criteria for abnormal stock fluctuation. The company found no recent public media reports of undisclosed material information that could significantly impact stock trading prices. Recent business operations remain normal with no major changes in internal or external operating environments. According to the board's analysis, the main reason for this stock price volatility is significant recent market price fluctuations in the company's main products silver and tin.

**Performance Overview**

**BAIC BluePark New Energy**: Subsidiary's September sales increased 30.15% year-over-year BAIC BluePark New Energy released its subsidiary's September production and sales report. Subsidiary Beijing New Energy Automobile Co., Ltd. sold 20,539 vehicles in September, up 30.15% year-over-year. Cumulative sales for the year reached 111,501 vehicles, up 64.34% year-over-year.

**Seres**: September new energy vehicle sales increased 19.44% year-over-year Seres announced that September 2025 new energy vehicle sales reached 44,700 units, up 19.44% year-over-year.

**BYD**: September new energy vehicle sales decreased 5.52% year-over-year BYD released its September production and sales report showing new energy vehicle sales of 396,300 units in September, down 5.52% year-over-year. September new energy vehicle exports totaled 71,256 units.

**VeriSilicon**: Expected Q3 revenue of 1.284 billion yuan VeriSilicon announced expected Q3 2025 revenue of 1.284 billion yuan, up 119.74% quarter-over-quarter and 78.77% year-over-year. The company expects significantly improved Q3 profitability, with single-quarter losses showing substantial narrowing both year-over-year and quarter-over-quarter.

**Yonghe Corporation**: Q3 net profit expected to increase 448% to 507% year-over-year Yonghe Corporation released a performance forecast for the first three quarters of 2025. According to preliminary calculations by the company's finance department, net profit attributable to shareholders for the first three quarters of 2025 is expected to be 456-476 million yuan, up 211.59% to 225.25% year-over-year. Q3 single-quarter net profit attributable to shareholders is expected to be 185-205 million yuan, up 447.64% to 506.85% year-over-year.

**Major Contract Signings**

**Xinjiang Communications Construction**: Expected to win 483 million yuan highway construction project bid Xinjiang Communications Construction announced receiving a bid award notice from Xinjiang Communications Investment Duku Expressway Investment and Development Co., Ltd., confirming the company as the winning bidder for the G3033 Kuitun-Dushanzi-Kuqa Expressway project construction road construction KDK-SGDL-1 section. The bid amount is 483 million yuan.

**Longquan Corporation**: Expected to win 50.76 million yuan project bid Longquan Corporation announced that on September 30, China General Nuclear Power Engineering Co., Ltd. published bid candidate announcements, confirming the company's wholly-owned subsidiary Wuxi New Peak Pipe Industry Co., Ltd. as the winning candidate for "BT Project and TY Project LOT44Ae Conventional Island Alloy Steel and Chrome-Controlled Steel Pipe Fittings." The total bid price is 50.76 million yuan, representing approximately 4.43% of the company's audited 2024 revenue.

**Runcon Corporation**: Expected to win 1.753 billion yuan onshore wind power project EPC contract Runcon Corporation announced that the company and controlling subsidiary Runcon Smart Energy Co., Ltd. recently won the bid for "Laoting Hengchang 256MW Onshore Wind Power Project Design and Construction General Contract (EPC)" with a total contract value of 1.753 billion yuan (including tax). The project is currently in the bid candidate announcement period, and there remains uncertainty regarding whether the company will receive the official bid award notice and ultimately sign a formal contract.

**InnoCare**: Subsidiary signs licensing agreement for orelabrutinib and 2 preclinical assets to Zenas InnoCare announced that wholly-owned subsidiary InnoCare Pharma Inc. signed a licensing agreement with Zenas BioPharma, Inc., licensing proprietary product orelabrutinib and 2 preclinical assets to Zenas for development, production, commercialization, or other utilization. The transaction includes a $100 million upfront payment and 7 million common shares, plus potential R&D and registration milestone payments totaling over $2 billion. Additionally, the company is entitled to tiered royalty fees up to high double digits based on annual net sales of licensed products. The agreement takes effect upon signing and continues until the end of the sales license period for licensed products.

**Share Changes**

**Hua Xing Yuan Chuang**: Suzhou Yuanke and Suzhou Yuanfen plan to reduce holdings by no more than 0.9% of company shares Hua Xing Yuan Chuang announced that Suzhou Yuanke and Suzhou Yuanfen (both employee shareholding platforms) plan to reduce their combined holdings by no more than 4 million shares through centralized bidding and block trading, representing no more than 0.9% of total share capital. Suzhou Yuanke plans to reduce holdings by no more than 2 million shares (no more than 0.45% of total capital), while Suzhou Yuanfen plans to reduce holdings by no more than 2 million shares (no more than 0.45% of total capital).